As Covid-19 shifts the world's at­ten­tion to biotech, Noubar Afeyan's Flag­ship builds $3.4B fund to fu­el new in­ven­tions. Here's the plan

A lit­tle more than a year ago, Flag­ship Pi­o­neer­ing rolled out a mon­ster fund with $1.1 bil­lion in it to bankroll the plat­form com­pa­nies they were cre­at­ing in­side their own labs. But it turns out, that was just the pre­lude to a much, much larg­er raise, as both cur­rent in­vestors — who’ve been reap­ing the re­wards of some boom­ing biotech stocks — join in with new in­vestors bet­ting on more in the years to come.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.